STOCK TITAN
  1. Home
  2. News
  3. LLY

Eli Lilly & Co. - LLY STOCK NEWS

Welcome to our dedicated page for Eli Lilly & Co. news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly & Co. stock.

Eli Lilly and Company (NYSE: LLY), founded in 1876 by Colonel Eli Lilly, is a global leader in the pharmaceutical industry, headquartered in Indianapolis, Indiana. With operations in 18 countries and products sold in approximately 125 countries, Eli Lilly is dedicated to pioneering life-changing discoveries through innovative drug development. The company focuses on several therapeutic areas including neuroscience, cardiometabolic, cancer, and immunology.

Key products in Eli Lilly’s portfolio include Verzenio for cancer treatment; Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes management; and Taltz and Olumiant for immunology. The company's recent financial performance has been robust, with Q1 2024 revenues increasing by 26% year-over-year to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

Eli Lilly continues to expand its manufacturing capabilities to meet growing demand, recently investing $5.3 billion in its Lebanon, Indiana site. This commitment supports the production of key therapies, particularly for chronic diseases like obesity and type 2 diabetes. The company’s innovative endeavors include the development of new treatments such as the once-weekly insulin efsitora alfa, which showed promising results in phase 3 trials for type 2 diabetes.

The company is also advancing its pipeline of oncology treatments with presentations of data on products like Verzenio, Retevmo, olomorasib, and imlunestrant at major medical conferences. Furthermore, Eli Lilly announced a major leadership change with Melissa Seymour joining as Executive Vice President of Global Quality, ensuring the sustained excellence of their product offerings.

Eli Lilly’s commitment to addressing significant health challenges is evident in its diverse product pipeline and ongoing clinical trials. The company remains focused on improving patient outcomes globally by harnessing advancements in biotechnology, chemistry, and genetic medicine.

News

Lilly to Participate in Evercore ISI HealthCONx Conference

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) announces participation in the Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D., Ph.D., to join a fireside chat at 3:50 p.m., Eastern time. The live audio webcast will be available on Lilly's Investor website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
News

Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma

Rhea-AI Summary
Eli Lilly and Company (LLY) extends tender offer to acquire POINT Biopharma Global Inc. (PNT) shares at $12.50 per share in cash, with the expiration now set for Nov. 16, 2023. Approximately 14.16% of the outstanding shares have been tendered as of Nov. 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
acquisition
-
News

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) has received FDA approval for Zepbound™ (tirzepatide) injection, the first obesity treatment activating GIP and GLP-1 hormone receptors. In clinical trials, adults lost an average of 48 lb. at the highest dose, with 1 in 3 patients losing over 58 lb. The drug is indicated for adults with obesity or those who are overweight with weight-related medical problems, promising hope for better weight management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
fda approval
News

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Rhea-AI Summary
OrsoBio, a clinical-stage biopharmaceutical company, completed a $60 million Series A financing, bringing the total capital raised to $97 million. The funding will support the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News

Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting

Rhea-AI Summary
Eli Lilly and Company will present updated data from studies of pirtobrutinib, a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 65th American Society of Hematology (ASH) Annual Meeting. The presentations will include safety and efficacy data for pirtobrutinib in multiple B-cell malignancies, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
-
News

Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) reported a 37% increase in revenue in Q3 2023, driven by growth from Mounjaro, Verzenio, and Jardiance. The company also earned $1.42 billion from the sale of rights for the olanzapine portfolio. Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue increased by 24%. Q3 2023 EPS was a loss of $0.06 on a reported basis and income of $0.10 on a non-GAAP basis. The company lowered its 2023 reported EPS guidance to $5.95 to $6.15 and non-GAAP EPS guidance to $6.50 to $6.70.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
earnings
News

Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

Rhea-AI Summary
Boehringer Ingelheim and Lilly have launched It Takes 2™, a health initiative to raise awareness about kidney disease and the benefits of complete testing. Clinical guidelines recommend using two tests, estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), to detect kidney disease. More than 35 million adults in the U.S. have chronic kidney disease, but 90% are unaware of their condition. The initiative is targeted towards individuals with type 2 diabetes or high blood pressure who are at greater risk for kidney disease. Hip-hop artist Rob Base has reimagined his hit song 'It Takes Two' as 'It Takes 2 - The Remix' to support the initiative.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
News

Lilly Declares Fourth-Quarter 2023 Dividend

Rhea-AI Summary
Eli Lilly and Company announces a dividend of $1.13 per share for the fourth quarter of 2023, payable on Dec. 8, 2023, to shareholders of record on Nov. 15, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
dividends
-
News

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

Rhea-AI Summary
Eli Lilly's Omvoh receives FDA approval for the treatment of ulcerative colitis, achieving primary and secondary endpoints in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
fda approval
News

Lilly to Participate in UBS Biopharma Conference 2023

Rhea-AI Summary
Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m., Eastern time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences

FAQ

What is the current stock price of Eli Lilly & Co. (LLY)?

The current stock price of Eli Lilly & Co. (LLY) is $746.2 as of November 15, 2024.

What is the market cap of Eli Lilly & Co. (LLY)?

The market cap of Eli Lilly & Co. (LLY) is approximately 713.4B.

What are Eli Lilly's core business areas?

Eli Lilly focuses on neuroscience, cardiometabolic, cancer, and immunology.

What are some of Eli Lilly's key products?

Key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, Humulin, Mounjaro, and Zepbound for diabetes, and Taltz and Olumiant for immunology.

How did Eli Lilly perform financially in Q1 2024?

Eli Lilly reported a 26% year-over-year increase in revenue to $8.77 billion, driven by strong sales of Mounjaro and Zepbound.

What recent investments has Eli Lilly made?

Eli Lilly has invested $5.3 billion to expand its manufacturing site in Lebanon, Indiana, supporting the production of treatments for chronic diseases like obesity and type 2 diabetes.

Who is the new Executive Vice President of Global Quality at Eli Lilly?

Melissa Seymour has been appointed as the new Executive Vice President of Global Quality, effective July 22, 2024.

What are some recent clinical trial results shared by Eli Lilly?

Eli Lilly shared positive results from trials for insulin efsitora alfa, Verzenio, Retevmo, olomorasib, and imlunestrant, showcasing their advancements in treatments for diabetes and cancer.

In how many countries does Eli Lilly operate?

Eli Lilly operates in 18 countries and its products are sold in approximately 125 countries.

What is the significance of Eli Lilly's recent investment in Lebanon, Indiana?

The investment will enhance production capacity for essential treatments like Zepbound and Mounjaro, aiming to meet the growing demand for these medicines.

What is the focus of Eli Lilly's ongoing research and development?

Eli Lilly's R&D focuses on innovative solutions for diabetes care, obesity, Alzheimer's disease, immune disorders, and cancer.

What are some common side effects of Eli Lilly's product Mounjaro?

Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Stock LLY logo
Eli Lilly & Co.

NYSE:LLY

LLY Rankings

#12 Ranked by Market Cap
#1941 Ranked by Dividends

LLY Stock Data

713.43B
950.41M
0.15%
83.46%
0.64%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS